BIO Share Price Performance
US$316.70
-16.21 (-4.87%)
19.5% overvalued intrinsic discount
US$265.00
Fair Value
Price US$316.70
AnalystLowTarget US$265.00
AnalystConsensusTarget US$348.00
AnalystHighTarget US$437.00
Fair ValueUS$265.00
Share Pricen/a
Bio-Rad Laboratories, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
BIO Community Narratives
AN
Fair Value US$265 19.5% overvalued intrinsic discount
Increasing Price Controls Will Limit Diagnostics Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$348 9.0% undervalued intrinsic discount
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$437 27.5% undervalued intrinsic discount
Global Healthcare Trends Will Fuel ddPCR Expansion Despite Risks
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
Key Takeaways Expansion in advanced molecular diagnostics and robust process chromatography growth are enhancing Bio-Rad's market position, revenue prospects, and operating leverage. Increased focus on consumables, lean operations, and geographic diversification is driving higher-margin recurring revenues and stability despite external cost and funding pressures.Read more
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$348
9.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
1.8% p.a.
Profit Margin
8.64%
Future PE
45.26x
Share price in 2028
US$437.17
Global Healthcare Trends Will Fuel ddPCR Expansion Despite Risks
Key Takeaways Accelerated adoption of digital PCR and precision diagnostics, along with market expansion, is expected to drive substantial revenue growth and margin improvement. Investments in automation, capacity, and regulatory expertise position Bio-Rad for operational efficiency, premium market share, and sustained outperformance versus peers.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$437
27.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
3.66% p.a.
Profit Margin
7.75%
Future PE
59.21x
Share price in 2028
US$534.01
Increasing Price Controls Will Limit Diagnostics Prospects
Key Takeaways Heightened pricing pressures, regulatory costs, and weakened public funding are expected to suppress revenue growth and constrain profitability. Operational risks and rapid technological change may disrupt execution, threaten product relevance, and increase volatility in earnings.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$265
19.5% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
1.93% p.a.
Profit Margin
8.15%
Future PE
35.82x
Share price in 2028
US$323.26
Recently Updated Narratives
AN
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
Fair Value: US$348 9.0% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Increasing Price Controls Will Limit Diagnostics Prospects
Fair Value: US$265 19.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Healthcare Trends Will Fuel ddPCR Expansion Despite Risks
Fair Value: US$437 27.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bio-Rad Laboratories, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -25.06
- 52.36%
- -26.43%
- 17.7%
About BIO
- Founded
- 1952
- Employees
- 7700
- CEO
- WebsiteView website
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
